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Abstract 
Little research has been done to evaluate the effect of adjusting for baseline in the analysis of 
repeated incomplete binary data through simulation study. In this article, covariate adjusted and 
unadjusted implementations of the following methods were compared in analyzing incomplete 
repeated binary data when the outcome at the study endpoint is of interest: logistic regression 
with the last observation carried forward (LOCF), generalized estimating equations (GEE), 
weighted GEE (WGEE), generalized linear mixed model (GLMM), and multiple imputation with 
analyses via GEE (MI).  Incomplete data mimicking several clinical trial scenarios were 
generated using missing completely at random (MCAR), missing at random (MAR), and missing 
not at random (MNAR) mechanisms.  Across the various analytic methods and scenarios 
covariate adjusted analyses generally yielded larger, less biased treatment effect estimates and 
larger standard errors compared with their unadjusted counterpart.  The net result of these factors 
was increased power from the covariate adjusted analyses without increasing type I error rates.  
Although all methods were biased in at least some of the MNAR scenarios, the type I error rates 
from LOCF exceeded 20% whereas the highest rate from any other method in any scenario was 
less than 10%.  LOCF also yielded biased results in MCAR and MAR data whereas the other 
methods were not biased or had smaller biases than LOCF.  These results support longitudinal 
modeling of repeated binary data over LOCF logistic regression of the study endpoint only.  
These results also support covariate adjustment for baseline severity in these longitudinal 
models.  
Key words:   GEE, GLMM, multiple imputation, weighted analysis 
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1. Introduction 
Binary outcomes derived from underlying continuous measures are commonly evaluated in 
randomized clinical trials to compare treatment effect.  For example, in diabetes clinical trials 
glycated haemoglobin (HbA1c) is a continuous measure that reflects average plasma glucose for 
several months (Sacks et al., 2002). It is commonly used as the primary efficacy outcome 
measure.  However, a clinically meaningful outcome is whether the endpoint HbA1c reaches the 
target of <7.0% (ADA, 2013).  Therefore, comparing the proportion of patients reaching HbA1c 
target of <7.0% between treatments based on a binary outcome is an important objective in 
diabetes trials.   
In longitudinal clinical trials patients are treated over a period of time and are evaluated at 
multiple time points.  Usually, the primary efficacy evaluation is based on the measurement at 
the last scheduled time point.  However, not all the patients complete the study. Some patients 
may withdraw before completing the study, and the measurement at the last scheduled time point 
will be missing.  Missing data occur commonly in longitudinal studies for various reasons, 
including lack of efficacy, safety, re-location, etc.  A historically common approach to handle 
missing data was to impute the missing observations with the last available observation of the 
patient, i.e., the last observation carried forward (LOCF) method.   However, LOCF requires 
restrictive assumptions that are unlikely to hold in practice, and this approach is generally not 
acceptable (NRC, 2010) 
Other analytic approaches for repeated binary data that do not require imputation include 
generalized estimating equations (GEE) (Liang and Zeger, 1986; Zeger and Liang, 1986).  Under 
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a missing completely at random mechanism (MCAR) (Rubin, 1976), GEE provides unbiased and 
consistent parameter estimates even when the working correlation matrix is mis-specified.  
However, under the missing at random mechanism (MAR) (Rubin, 1976) parameter estimates 
based on GEE can be biased.  A weighted generalized estimating equations approach (Robins et 
al. 1995; and Fitzmaurice et al. 1995) extends conventional GEE and provides consistent 
parameter estimates under MAR when the dropout model is correctly specified.  In this 
approach, an individual’s contribution is weighted by the inverse probability of dropout at the 
given time. 
Likelihood-based generalized linear mixed model (GLMM) analyses of the available cases have 
also been widely used for the analysis of repeated binary data, generally under the assumption of 
MAR although some approximations to direct-likelihood require the more stringent MCAR 
assumption (Wolfinger and O’Connell, 1993).   
Multiple imputation approaches (Rubin, 1987; Schafer, 1999; Shieh, 2003; Li et al., 2006; 
Carpenter and Kenward, 2013; and van Buuren, 2014) are commonly applied to continuous 
incomplete longitudinal data and can therefore be used to impute the continuous outcome from 
which the binary responses are derived without some of the restrictive assumptions that limit 
LOCF.  After imputation, the resulting complete data sets can be analyzed with either GEE or 
likelihood-based methods.   
Lipkovich et al. (2005) compared the performance of MI followed by GEE analysis with GLMM 
and GEE analyses of available cases in estimating treatment differences for binary outcomes 
derived from underlying continuous responses.  The MI-based approach performed better than 
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GEE and GLMM in terms of precision, power, and type I error rate under MAR.  However, 
under the missing not at random (MNAR) mechanism, all three methods yielded biased results.  
Liu and Zhan (2011) also conducted simulations to compare GLMM, GEE, and several MI 
approaches for the analysis of repeated binary responses with missing data in evaluating the 
treatment effect at study endpoint.  Results indicated that GLMM performed better than GEE and 
MI approaches in terms of controlling type I error rate under MAR. 
In many clinical settings the baseline severity is linked to the probability of achieving a target 
level of symptom severity.  For example, in diabetes baseline HbA1c levels influence whether 
the patient can achieve the HbA1c target of <7.0%.  Therefore, adjusting for baseline severity 
may improve analytic performance in these situations.  However, little research has been done to 
evaluate the effect of adjusting for initial disease severity in the analysis of repeated binary data 
with missing values.  The present research evaluates the performance of the covariate adjusted 
and unadjusted analyses of repeated binary outcomes in terms of type I error rate, power, 
precision, and bias across several common statistical approaches.  Focus is on evaluating the 
treatment effect at the study endpoint. We note that by the treatment effect we aim at the 
“efficacy estimand” that is the treatment effect, assuming had all patients who discontinued the 
trial would have completed the study while complying with the protocol. 
2. Statistical Methods 
For the analysis of the single outcome at study endpoint without repeated measures, logistic 
regression with LOCF was used.  For repeated binary outcome analyses GEE, WGEE, GLMM, 
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and MI approaches were used, and the study endpoint contrast was derived from the repeated 
measures analysis.  Details of each analysis are described below. 
Logistic regression: 
For the analysis of a single binary outcome at study endpoint, let Yi=1 represent that the ith 
patient achieved the HbA1c target of <7.0% at the study endpoint, and Yi=0 otherwise.  Let β be 
a vector of regression coefficients; Xi be a vector of covariates such as treatment indicator and 
baseline HbA1c; and pi = pr(Yi=1| Xi, β)=E (Yi | Xi, β).  Then the logistic regression model can be 
expressed as: 
                                              logit (pi )= log (
  
    
) =    
  β                                         (1) 
With LOCF there is no missing data and the key assumption is that patients’ observations would 
not have changed had they stayed in the trial.  Logistic regression was implemented in the 
present study using SAS PROC GENMOD (SAS, 2008). 
Generalized Estimating Equations (GEE) 
For the analysis of a repeated binary outcome, let Yit=1 represent that the ith patient achieved 
HbA1c target of <7.0% at time t, and Yit =0 otherwise; Xit be the vector of covariates for the ith 
patient at time t; let Yi =                   
 ,  Xi= (Xi1 , Xi2 ,…, XiT ), and T be the number of 
scheduled study visits at which the data are collected. Let  β be the vector of regression 
coefficients;  and pi (β)= pr(Yi=1| Xi, β)=E (Yi | Xi, β). Then, the GEE proposed by Liang and 
Zeger (1986) and Zeger and Liang (1986) takes the form 
                                              U(β  ∑    
 
     
  (        )                                      (2) 
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where              and    is a “working” covariance matrix. SAS PROC GENMOD (SAS, 
2008) was used to implement GEE in the present study.   The key missing data assumption for 
GEE is that the missing data arise from a MCAR mechanism (Molenberghs and Kenward, 2007).  
 
Weighted Generalized Estimating Equations (WGEE) 
The WGEE method proposed by Robins et al. (1995) and Fitzmaurice et al. (1995) is less 
restrictive than standard GEE in that the key missing data assumption is that the missing data 
arise from an MAR mechanism - given that the probabilities of dropout for each subject are 
correctly specified (Molenberghs and Kenward, 2007). Fitzmaurice et al. (1995) provided a 
formulation of the WGEE method based on the article by Robins et al. (1995). Under this 
approach, equation (2) is modified as: 
                               U(β  ∑
 
  
  
 
 
     
  (        )                                                       (3) 
where    is the estimated probability of ith patient following the dropout pattern that was 
observed for that patients. That is, for a patient who discontinued at visit d,    is the probability 
of patient’s remaining in the study through visit (d-1) and discontinuing at visit d; for a patient 
who had completed the trial,    is the probability of that patient remaining in the study through 
the last scheduled visit. Therefore an individual’s contribution in estimating equation is weighted 
by the inverse probability of observing patient’s discontinuation pattern.   In the present study 
WGEE was implemented using PROC GENMOD (SAS, 2008) to estimate the dropout 
probabilities and incorporate the weightings and conduct analysis. 
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Generalized Linear Mixed Model (GLMM) 
The GLMM extends the generalized linear model by incorporating normally distributed random 
parameters for individual subjects (Breslow and Clayton, 1993) under the assumption of MAR. 
The fixed-effect inference is conditional on random parameters and has a subject-specific 
interpretation.  The form of GLMM based on the logit link function to fit the response 
probability, pit, at time point t is as 
                                 logit (pit )=     
  β +     
                                                                           (4) 
where β is the vector of the fixed-effect parameters,    is the vector of random subject 
parameters and          , and     and     and the vectors of known covariates.  In the present 
study, GLMM was implemented using PROC GLIMMIX in SAS (SAS, 2008). 
Multiple Imputation (MI): 
MI is an extension of single imputation where the missing data are imputed several times, say m 
times. Then each of the m complete data sets is analyzed with standard methods, and the results 
of the m analyses are combined according to Rubin’s rule [Rubin, 1987].  MI usually assumes an 
MAR mechanism. The following process was implemented for the multiple imputation method. 
 1. Bayesian regression, which included earlier values as predictors, was used to impute 
the missing data with a separate predictive distribution for each treatment group [Rubin, 1987].  
The missing continuous HbA1c values were imputed first with the SAS MI procedure (SAS, 
2008).  Next, the continuous outcomes were dichotomized into binary response data according to 
whether they were <7.0% or not.  We generated m=30 complete data sets. 
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 2. The GEE model as previously described was used to analyze each of the 30 imputed 
complete data sets for the repeated binary response, and 30 sets of parameter estimates were 
obtained. 
 3. The 30 estimates and associated standard errors were combined into the final estimates 
with SAS PROC MIANALYZE (SAS, 2008) according to Rubin’s rule. 
3. Simulation 
3.1 Simulation setting 
The continuous HbA1c values (%) at each visit were simulated based on a multivariate normal 
distribution with mean profiles (Table 1) and variance-covariance matrix with elements σi,j=ρ σi 
σj, where ρ was the correlation between the repeated outcomes. The binary outcome was 
constructed based on whether the HbA1c value was <7.0% or not.  Data were simulated based on 
inputs obtained from actual diabetes clinical trials.  A compound-symmetry correlation matrix 
was used, with and the variance (σi
2
) increasing over time from visit 1 (at baseline) to 
visit 4 (1.0, 1.0, 1.2, 1.4).  The sample size of 50 and 200 per treatment group were used to 
mimic phase 2 and phase 3 trial settings, respectively.   
Incomplete data sets were then generated from the complete data sets using 3 rates of missing 
data and 3 missing data mechanisms.  Rates of missing data were either 45% in both treatments 
groups or 25% in one treatment group and 45%  in the other.  Missingness mechanisms were 
either MCAR, MAR, or MNAR.  In MCAR the outcomes did not differ for patients that 
completed compared with those who dropped out.  In MAR the probability of a value (  ) being 
missing depended on the observed value at the previous visit (    ), expressed as logit (p (   
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missing |     )=         .  The value   =1.5 was used in the dropout model, and the value   
was chosen for each treatment group to achieve the desired rates of missing data.  In MNAR the 
probability of a value (  ) being missing depended on the value itself (  ), expressed as 
logit (p (   missing |   )=       .  The value   =0.4 was used in the dropout model, and the 
value   was chosen for each treatment group to achieve the desired rates of missing data.  For 
simplicity, only monotone missingness was considered.  For each scenario 2000 data sets were 
simulated. 
The performance of different analysis methods was evaluated based on bias ( ̂ -    in scenarios 
when there was no difference between treatments at endpoint, relative bias (
 ̂   
  
 100) in 
scenarios where treatments did differ at endpoint.  Methods were also compared based on 95% 
confidence interval (CI) coverage (using normal theory approximation), standard errors (SE) 
(average of  SEs from the 2000 simulations), and type I error rate for scenarios with no 
difference between treatments and power for scenarios where treatments differed.  ̂ is the 
estimate of log odds ratio for unadjusted or adjusted analysis.    is the “true” log odds ratio for 
the unadjusted or adjusted analysis which is based on estimates from the values obtained by 
averaging results from the corresponding complete data sets.   
3.2. Simulation Results 
Tables 2 and 3 show the simulation results for different methods:  covariate adjusted/ unadjusted 
logistic regression (Adj.logit/Unadj.logit) with LOCF method, covariate adjusted/unadjusted 
generalized estimating equations (Adj.GEE/Unadj.GEE), covariate adjusted/unadjusted weighted 
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generalized estimating equations (Adj.WGEE/Unadj.WGEE),  covariate adjusted/unadjusted 
generalized linear mixed model (Adj.GLMM/Unadj.GLMM), and covariate adjusted/unadjusted 
generalized estimating equations on the basis of multiple imputation  (Adj.MI/ Unadj.MI).  
Under MCAR, LOCF appreciably inflated type I error when rates of missing data differed 
between treatments.  All analyses yielded the anticipated nominal type I error rate when rates of 
missing data were equal for the two treatments. MI analyses yielded the lowest type I error rate 
(<3%).  
All analyses yielded relatively unbiased estimates with the absolute bias <0.06 for the no 
treatment effect case, and relative bias ≤16% for the strong treatment effect case, except for 
LOCF. LOCF had biases 7-18 times greater than other methods for the no treatment effect case 
with unequal missing proportions and relative bias up to 35% for the strong treatment effect case.  
All analyses produced CIs with coverage close to their nominal level except for LOCF analysis 
which was associated with coverage lower than the nominal level, with the MI analysis 
exceeding the nominal level.  For the strong treatment effect case, adjusted analyses yielded 
greater, less biased treatment effect estimates but also larger SEs compared to the unadjusted 
analyses, resulting in increased power with the large sample size.  However, slightly lower 
power of the adjusted analyses was observed with the small sample size. 
Under MAR,  Unadj.GEE, Unadj.GLMM, WGEE, and LOCF methods inflated type I error with 
unequal missing data rates.  All analyses preserved type I error rate with the equal missing 
proportion case .  MI analyses had the lowest type I error rate, <4%.  All analyses yielded 
relatively unbiased estimates with the absolute bias ≤0.07 for the no treatment effect case, except 
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for LOCF, Unadj.GLMM and WGEE.  However, for the strong treatment effect case LOCF, 
GLMM, and WGEE yielded significantly biased estimates with relative bias up to 66.1%.  In 
general, adjusted analyses had less bias than their unadjusted counterparts. All analyses produced 
CIs with coverage close to the nominal level except for LOCF, Unadj.GLMM, and WGEE, 
which yielded coverage lower than the nominal level, while MI analysis exceeded their nominal 
level.  For the strong treatment effect case, adjusted analyses yielded greater, less biased 
treatment effect estimates and SEs compared to the unadjusted analyses, but resulted in increased 
power in general.  
Under MNAR,  all analyses inflated type I error rate except for MI and WGEE.  For the strong 
treatment effect case with equal missing data rates all analyses except for LOCF and 
Unadj.GLMM produced relatively unbiased estimates (relative bias <=11.7%). However, for the 
strong treatment effect case with unequal missing data rates all analyses except for WGEE 
yielded significantly biased estimates with relative bias up to 37.9%. 
5. Clinical Trial Examples 
The methods tested in the simulation study were also applied to data from five diabetes clinical 
trials in which an active drug (treatment) was compared with different comparators over 52 
weeks. The missing data proportions for the treatment and comparators were 15.1%, 23.9%; 
12.8%, 12.2%; 22.7%, 26.9%; 23.4%, 20.3%; and 19.4%, 20.0% for study 1 to 5, respectively. 
The proportions of patients who achieved HbA1c target of <7.0% at the final visit for the 
treatment and comparators were 73%, 55%; 54%, 31%; 64%, 53%; 61%, 48%; and 64%, 38% 
for study 1 to 5, respectively. The analyses were conducted on proportion of patients whose 52-
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week endpoint HbA1c was <7.0%.  The LOCF analyses were implemented using logistic models 
with a factor for treatment only (Unadj.Logit) and with baseline HbA1c (Adj.Logit).  The models 
for the GEE, WGEE, GLMM, and MI analyses included treatment, visit, and treatment-by-visit 
interaction, with or without baseline HbA1c, and baseline HbA1c-by-visit interaction. An 
unstructured covariance matrix or working correlation matrix was used except for WGEE where 
an independent working correlation matrix was used which was considered as a best fit 
(Fitzmaurice et al. 1995).  Results are displayed in Table 4 and Figure 1.  As in the simulated 
data, covariate adjusted methods yielded larger treatment effects compared to their unadjusted 
counterparts; and standard errors were larger and p values smaller from adjusted analyses for all  
studies except for study 4, where adjusted and unadjusted methods yielded comparable effects 
and standard errors.  The possible reason is that that the treatment group had a slightly lower 
mean baseline HbA1c value compared to the comparator group in study 4, while the baseline 
HbA1c was slightly higher in the treatment group or close to the comparator in other studies. The 
differences (treatment-comparator) in baseline HbA1c were -0.02%, 0.07%, 0.04%, -0.04%, and 
0.12% for study 1 to 5, respectively. 
6. Summary and Discussion 
In longitudinal clinical trials it is often reasonable to assume missing data arise from an MAR 
mechanism (Verbeke and Molenberghs, 2000; NRC, 2010).   Dichotomized continuous 
outcomes or other binary measures are often of interest.  Therefore, appropriate modeling of 
incomplete longitudinal binary clinical trial data is important.  
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Longitudinal binary data analyses with incomplete measures have been studied extensively in the 
literature (Albert, 1999; Cnaan et al. 1997; Fitzmaurice et al. 1994). However, little research has 
been done to evaluate the effect of adjusting for baseline in the analysis of repeated incomplete 
binary data through simulation study. Simulations were conducted over a variety of scenarios in 
this article to examine how including or not including baseline severity as a covariate influenced 
results across several methods for analyzing incomplete longitudinal binary responses.  The 
covariate adjusted analyses generally yielded larger, less biased treatment effect estimates and 
larger standard errors compared with their unadjusted counterpart.  The net result of these factors 
was increased power from the adjusted analyses without increasing type I error rate.  Results 
from five phase 3 diabetes trials were consistent with the simulation findings.   
In regards to how the various methods handled missing data, with MNAR data all methods 
except for WGEE yielded biased results in at least some scenarios and all methods except MI 
and WGEE inflated type I error rates in some scenarios.  With MCAR data LOCF yielded biased 
results, inflated type I error rates and had poor CI coverage, whereas results from other methods 
were not biased.  With MAR data, LOCF again yielded biased results. GLMM also yielded 
biased results.  MI yielded unbiased results, as expected, because it assumes MAR.  Results from 
GEE were relatively unbiased.  Counter to expectation, results from WGEE were biased in the 
MAR scenarios where dropout rates differed but were not biased when dropout rates were equal.   
Recall the description in section 3.1 of the dropout mechanisms applied to delete data. 
In MAR the probability a value (  ) being missing depended on the observed value at the 
previous visit (    ), expressed as logit (p (   missing |     )=         .  The value   
=1.5 was used in the dropout model and the value   was chosen for each treatment 
group to achieve the desired rates of missing data. 
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Thus, when the dropout rate was equal in the two treatments they shared a common intercept (  , 
but when dropout rates differed the intercepts differed.  That is, there were separate dropout 
models for each treatment.  However, in the WGEE analyses a single model was used to estimate 
the weights for both treatment groups.  Therefore, in scenarios where the dropout rates differed, 
the model used to estimate the weights was not the same as the model used to generate the 
missing data.  In addition, for MAR logit (p (   missing |     )=         .   
However, the weights were estimated using logit (p (   missing |     )=       . 
The issue of having the same or separate models by treatment group applies to the imputation 
model in MI.  In the present study MI was implemented with separate imputation models for 
each treatment, thereby accommodating different dropout models for each treatment in the 
scenarios where dropout rates differed.  
These results illustrate the potential importance of modeling considerations in the handling of 
missing data.  For methods that explicitly impute missing values or model dropout, it may be 
useful to consider separate models for each treatment or for groups of treatments (e.g., all doses 
of a drug in one group, placebo in the other), especially when rates, timing, and/or reasons for 
dropout differ.  
Although these modeling considerations are important, they should not be taken as motivation to 
return to the use of ad hoc methods.  For example, in the MAR scenarios where WGEE yielded 
type I error rates of 6.1% – 6.9%, the corresponding rates from LOCF were 20.6% - 23.5%. 
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In this article, we only allowed missingness to depend on outcomes prior to (MAR) or at the 
current visit (MNAR) and monotone missingness. Evaluation of model performance under the 
scenarios where missingness depends on baseline covariates, and/or with non-monotone 
missingness is a future research topic. 
The present investigation focused on only one of the many modeling considerations, fitting a 
single covariate that describes baseline severity.  Results support including baseline severity as a 
covariate in analyses of incomplete longitudinal binary outcomes.    
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Appendix 
Examples of SAS code 
************************************************************************** 
Adjusted and Unadjusted GEE models 
**************************************************************************; 
proc genmod data= simu_data; 
class subjid  visit trt ; 
model target_a1c=   trt  <baselinehba1c> visit visit*trt <baselinehba1c*visit> /dist=bin ; 
repeated subject=subjid/type=un; 
lsmeans visit*trt /diff; 
run; 
 
************************************************************************** 
Adjusted and Unadjusted GLMM models 
**************************************************************************; 
proc glimmix data= simu_data empirical ;  
nloptions maxiter=100 tech=NRRIDG;  
class subjid visit trt; 
model target_a1c = trt  < baselinehba1c > visit visit*trt <baselinehba1c*visit>/dist=bin ; 
random int / subject=subjid; 
lsmeans visit*trt/diff; 
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run;  
 
************************************************************************** 
Adjusted and Unadjusted MI  
**************************************************************************; 
 
proc mi data=one seed=1305417 nimpute=30 out=outone; 
by trt; 
var baselinea1c v1 v2 v3; 
monotone reg(v2= baselinea1c v1);  
monotone reg(v3= baselinea1c v1 v2 ); 
run; 
 
ods output diffs=MIdiffs (where= (visit in (3) and _visit in (3))rename=(  
stderr=MIse estimate=MIest)); 
proc genmod data=outone descending; 
class subjid   visit trt;by _imputation_;  
model target_a1c= <baselinea1c> trt  visit <baselinea1c*visit> visit*trt/dist=bin ; 
repeated subject=subjid/type=un; 
lsmeans visit*trt/pdiff; 
 
proc mianalyze data=MIdiffs; 
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modeleffects Miest; 
stderr mise; 
run; 
 
************************************************************************** 
Adjusted and Unadjusted WGEE models 
**************************************************************************; 
%MACRO WGEE( 
        INPUTDS =, 
        VISVAR  =, 
        STRVIS  =, 
        ENDVIS  =, 
        TRTVAR  =, 
        SUBJVAR =, 
        Y       =, 
        CLASVAR =, 
        DMODL   =, 
        DCOVTYPE=, 
        MCOVTYPE=, 
        TRIM    =); 
 
PROC SORT DATA=&INPUTDS OUT=ONE1; 
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  BY &SUBJVAR &VISVAR; 
  WHERE &STRVIS<=&VISVAR<=&ENDVIS; 
RUN; 
 
DATA _LASTVIS; 
  SET ONE1; 
  BY &SUBJVAR &VISVAR; 
  IF LAST.&SUBJVAR; 
  LASTVIS=&VISVAR; 
  KEEP &SUBJVAR LASTVIS; 
RUN; 
 
DATA TWO1; 
  MERGE ONE1 _LASTVIS; 
  BY &SUBJVAR; 
  IF &VISVAR<LASTVIS THEN DROP=0; 
  IF &VISVAR=LASTVIS AND LASTVIS<&ENDVIS THEN DROP=1; 
  IF &VISVAR=LASTVIS AND LASTVIS=&ENDVIS THEN DROP=0; 
RUN; 
 
%*************************************************************************; 
%*Visitwise logistic regression analysis of dropout to determine weights *; 
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%*************************************************************************; 
proc sort data=TWO1; by &TRTVAR &SUBJVAR; run; 
ODS LISTING CLOSE; 
 PROC GENMOD DATA=TWO1 DESCENDING; 
   CLASS &CLASVAR; 
   MODEL DROP=&DMODL/DIST=BIN PRED TYPE3; 
  
   REPEATED SUBJECT=&SUBJVAR/WITHINSUBJECT=&VISVAR TYPE=&DCOVTYPE 
            CORRW ECOVB ECORRB MCOVB MCORRB MODELSE; 
  
   ODS OUTPUT OBSTATS=_PRED GEEEMPPEST=EMPEST GEEMODPEST=MODEST 
              GEENCORR=MODCORR GEENCOV=MODCOV GEEWCORR=WORKING 
              GEERCORR=EMPCORR GEERCOV=EMPCOV  
              TYPE3=TYPE3; 
RUN; 
 
ODS LISTING; 
 
%************************************************; 
%* Merge probability of dropout with main data  *; 
%************************************************; 
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DATA _PRED2; 
  SET _PRED; 
  RENAME DROP=PDROP; 
RUN; 
 
DATA THREE1; 
  MERGE TWO1 _PRED2; 
  IF PRED NE . ; 
RUN; 
 
%****************************************************************************
***; 
%* Accumulate inverse probability weights over visits and output new data set  *; 
%****************************************************************************
***; 
proc sort data=THREE1; by &SUBJVAR; run; 
DATA _WGT (KEEP=&SUBJVAR WI); 
  SET THREE1; 
  BY &SUBJVAR; 
  RETAIN WI; 
  IF FIRST.&SUBJVAR THEN WI=1; 
  IF NOT LAST.&SUBJVAR THEN WI=WI*(1-PRED); 
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  IF LAST.&SUBJVAR THEN DO; 
    IF &VISVAR<&ENDVIS THEN WI=WI*PRED; 
        ELSE WI=WI*(1-PRED); 
        WI=1/WI; 
        OUTPUT; 
  END; 
RUN; 
 
%*************************************************; 
%* Add inverse probability weight to data set and*; 
%* trim weight to eliminate unstable weights     *; 
%*************************************************; 
DATA FOUR; 
  MERGE THREE1 _WGT; 
  WI_TR=MIN(WI, &TRIM); 
  BY &SUBJVAR; 
RUN; 
 
PROC GENMOD DATA=FOUR DESCENDING; 
   SCWGT WI; 
   CLASS &CLASVAR; 
   MODEL &Y =<baselinea1c> VISIT trt <baselinea1c*visit> VISIT*trt/DIST=bin  TYPE3; 
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   REPEATED SUBJECT=&SUBJVAR/ TYPE=&MCOVTYPE CORRW; 
   LSMEANS &TRTVAR*&VISVAR/CL DIFF ILINK; 
    
RUN; 
 
 
%MEND WGEE; 
%WGEE( 
  INPUTDS   =dataset, 
  VISVAR    =VISIT, 
  STRVIS    =1, 
  ENDVIS    =3, 
  TRTVAR    =trt, 
  SUBJVAR   =subjid, 
  Y         =target_a1c, 
  CLASVAR   =subjid VISIT trt, 
  DMODL     =baselinea1c a1c trt baselinea1c*trt a1c*trt, 
  DCOVTYPE  =ind, 
  MCOVTYPE  =ind, 
  TRIM      =20); 
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Figure 1.  Log odds ratio and 95% CI by study and method  
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Table 1. Mean treatment profiles in simulation model 
Hypothesis  visit1 HbA1c 
(%) (% 
achieved 
target)* 
visit2  HbA1c 
(%)(%  
achieved 
target) 
visit3  HbA1c 
(%)(%  
achieved 
target) 
visit4  HbA1c 
(%)(%  
achieved 
target) 
No treatment 
effect 
Treatment 
8.5 (0%) 7.6 (27%) 7.3 (39%) 7.0 (50%) 
 Comparator 8.5 (0%) 7.6 (27%) 7.3 (39%) 7.0 (50%) 
Strong 
treatment 
effect 
Treatment 
             8.5 
(0%) 7.6 (27%) 7.3 (39%) 7.0 (50%) 
 Comparator 
8.5 (0%) 7.8 (21%) 7.6 (29%) 
           7.4 
(37%) 
* HbA1c (%) is a continuous variable from which a binary response of whether the patient 
achieved the target HbA1c of 7.0% is derived. We let all baseline (visit 1) HbA1c values be 
>7.0% because this usually is one of the inclusion criteria in diabetes trials. 
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Table 2: Summary of analysis results from 2000 simulations with no treatment effect 
   (45%, 45%)* (25%, 45%)* 
 N  Bias SE Cov (%)  Type I error rate (% ) Bias SE Cov (%)  Type I error rate (% ) 
MCAR 50 Unadj.logit 0.01 0.41 95 5.1 0.15 0.41 92 7.9 
  Adj.logit 0.00 0.45 95 4.9 0.18 0.45 93 7.2 
  Unadj.GEE 0.01 0.53 95 5.2 0.02 0.50 95 5.4 
  Adj.GEE 0.01 0.62 95 5.2 0.03 0.57 95 4.8 
  Unadj.GLMM 0.01 0.60 95 5.1 0.02 0.56 95 4.9 
  Adj.GLMM 0.01 0.65 95 4.6 0.03 0.60 95 4.8 
  Unadj.MI 0.00 0.50 98 2.1 0.00 0.48 97 3.2 
  Adj.MI -0.02 0.57 98 1.9 0.01 0.54 97 2.6 
  Unadj.WGEE 0.01 0.57 97 3.2 0.05 0.52 96 3.9 
  Adj.WGEE 0.00 0.63 96 4.0 0.06 0.58 96 4.1 
 200 Unadj.logit 0.01 0.20 95 5.1 0.15 0.20 89 11.0 
  Adj.logit 0.01 0.22 95 5.1 0.17 0.22 88 11.9 
  Unadj.GEE 0.01 0.26 96 4.4 0.01 0.25 95 5.1 
  Adj.GEE 0.01 0.30 95 4.8 0.01 0.27 94 5.7 
  Unadj.GLMM 0.01 0.29 96 4.5 0.01 0.27 95 5.0 
  Adj.GLMM 0.01 0.31 95 5.0 0.01 0.29 94 5.7 
  Unadj.MI 0.00 0.25 98 2.0 0.02 0.24 97 3.3 
  Adj.MI 0.01 0.28 98 2.1 0.02 0.26 97 3.5 
  Unadj.WGEE 0.01 0.27 97 2.7 0.04 0.25 96 4.2 
  Adj.WGEE 0.01 0.30 97 3.4 0.05 0.28 95 5.2 
MAR 50 Unadj.logit 0.01 0.42 95 5.2 0.24 0.41 90 10.1 
  Adj.logit 0.00 0.46 94 5.5 0.28 0.46 90 10.5 
  Unadj.GEE 0.02 0.51 94 5.7 -0.04 0.48 94 6.1 
  Adj.GEE 0.01 0.58 95 5.3 -0.03 0.55 95 5.2 
  Unadj.GLMM 0.02 0.58 95 4.9 -0.11 0.55 94 5.6 
  Adj.GLMM 0.01 0.62 95 4.4 -0.07 0.58 95 4.7 
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  Unadj.MI 0.00 0.51 97 3.0 -0.01 0.48 97 3.2 
  Adj.MI -0.01 0.58 97 2.6 -0.02 0.55 97 2.5 
  Unadj.WGEE 0.03 0.66 94 5.5 0.13 0.59 95 5.5 
  Adj.WGEE 0.03 0.67 94 5.6 0.13 0.61 94 6.3 
 200 Unadj.logit 0.01 0.21 95 5.1 0.23 0.20 79 20.6 
  Adj.logit 0.01 0.23 94 6.0 0.28 0.23 77 23.5 
  Unadj.GEE 0.01 0.25 94 6.0 -0.05 0.24 94 6.1 
  Adj.GEE 0.01 0.28 94 5.7 -0.03 0.27 94 5.9 
  Unadj.GLMM 0.01 0.28 94 5.6 -0.11 0.27 93 7.3 
  Adj.GLMM 0.01 0.29 94 5.7 -0.07 0.28 94 5.9 
  Unadj.MI 0.01 0.25 96 3.8 0.02 0.24 96 3.7 
  Adj.MI 0.01 0.28 96 3.7 0.02 0.26 97 3.4 
  Unadj.WGEE 0.00 0.38 96 3.8 0.19 0.33 94 6.1 
  Adj.WGEE 0.00 0.35 96 4.4 0.17 0.31 93 6.9 
MNAR 50 Unadj.logit 0.00 0.41 95 5.1 0.13 0.41 93 6.5 
  Adj.logit 0.00 0.45 96 4.2 0.16 0.45 94 6.0 
  Unadj.GEE 0.02 0.53 95 5.2 -0.10 0.49 94 6.2 
  Adj.GEE 0.02 0.61 95 5.3 -0.10 0.56 93 6.5 
  Unadj.GLMM 0.02 0.59 95 4.6 -0.14 0.55 94 6.2 
  Adj.GLMM 0.02 0.64 95 4.5 -0.12 0.59 93 6.3 
  Unadj.MI -0.01 0.50 98 2.4 -0.08 0.47 96 3.4 
  Adj.MI -0.02 0.57 98 2.1 -0.10 0.53 97 3.2 
  Unadj.WGEE 0.02 0.57 97 3.3 -0.01 0.52 97 3.3 
  Adj.WGEE 0.01 0.63 96 4.4 -0.04 0.57 96 4.3 
 200 Unadj.logit 0.00 0.20 94 5.8 0.13 0.20 90 10.3 
  Adj.logit 0.00 0.22 95 5.2 0.15 0.22 89 11.3 
  Unadj.GEE 0.01 0.26 94 6.0 -0.10 0.24 92 7.8 
  Adj.GEE 0.01 0.29 94 5.6 -0.10 0.27 92 8.4 
  Unadj.GLMM 0.01 0.29 94 5.7 -0.13 0.27 91 8.6 
  Adj.GLMM 0.01 0.30 95 5.3 -0.11 0.28 92 8.4 
  Unadj.MI 0.01 0.25 97 2.8 -0.06 0.23 96 4.2 
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  Adj.MI 0.00 0.28 98 2.5 -0.07 0.26 96 3.8 
  Unadj.WGEE 0.01 0.28 97 3.5 -0.01 0.25 96 4.0 
  Adj.WGEE 0.01 0.30 96 4.2 -0.03 0.27 95 4.7 
* Percentage of missing data for comparator and treatment, respectively; Cov: coverage of 95% CI;  Est: - log odds ratio; 
Boldface font indicates that the type I error rate is beyond 2 SEs of simulations.
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Table 3: Summary of analysis results from 2000 simulations with strong treatment effect 
   (45%, 45%)* (25%, 45%)* (45%, 25%)* 
 N  Est 
RelBias 
(%) SE 
Cov 
(%)  
Power 
(%)  
Est 
RelBias 
(%) SE 
Cov 
(%)  
Power 
(%)  
Est Rel 
Bias 
(%) SE 
Cov 
(%)  
Power 
(%)  
MCAR 50 Unadj.logit -0.48 -10.3 0.42 95 19.7 -0.36 -31.7 0.42 94 14.8 -0.63 18.5 0.42 95 30.3 
  Adj.logit -0.56 -11.7 0.47 94 22.4 -0.43 -32.8 0.46 92 15.5 -0.75 17.0 0.47 95 35.0 
  Unadj.GEE -0.55 3.6 0.55 95 17.1 -0.55 4.7 0.51 95 19.5 -0.56 6.6 0.51 96 19.4 
  Adj.GEE -0.68 6.0 0.63 95 18.0 -0.68 5.9 0.59 95 21.4 -0.69 7.0 0.59 95 20.3 
  Unadj.GLMM -0.60 13.0 0.61 95 16.1 -0.61 16.0 0.57 95 18.8 -0.61 15.1 0.57 95 17.9 
  Adj.GLMM -0.71 11.2 0.66 95 17.5 -0.71 11.3 0.61 95 20.6 -0.71 11.4 0.62 95 19.2 
  Unadj.MI -0.54 2.7 0.51 98 14.2 -0.55 4.0 0.49 97 17.6 -0.56 5.5 0.49 97 16.0 
  Adj.MI -0.65 2.1 0.59 98 14.1 -0.66 3.3 0.56 98 17.5 -0.67 4.6 0.56 97 16.5 
  Unadj.WGEE -0.53 -0.3 0.58 97 12.5 -0.51 -4.4 0.53 96 14.8 -0.57 7.2 0.54 97 16.4 
  Adj.WGEE -0.66 2.8 0.65 96 14.5 -0.63 -2.2 0.60 96 17.4 -0.69 8.6 0.60 96 19.0 
 200 Unadj.logit -0.47 -11.7 0.21 95 62.3 -0.35 -33.1 0.21 85 39.8 -0.60 12.8 0.21 94 82.1 
  Adj.logit -0.55 -14.5 0.23 94 67.9 -0.42 -35.1 0.23 82 44.5 -0.71 10.7 0.23 95 89.4 
  Unadj.GEE -0.55 2.9 0.27 95 53.5 -0.54 2.8 0.25 94 58.6 -0.53 0.2 0.25 95 55.3 
  Adj.GEE -0.65 1.2 0.30 95 57.5 -0.65 1.2 0.28 94 62.7 -0.64 -0.7 0.28 95 63.0 
  Unadj.GLMM -0.59 11.7 0.30 95 51.5 -0.60 12.8 0.28 93 58.4 -0.58 8.9 0.28 95 53.9 
  Adj.GLMM -0.67 4.9 0.31 94 57.5 -0.67 5.3 0.29 94 62.7 -0.66 3.1 0.29 96 62.2 
  Unadj.MI -0.54 2.3 0.25 97 58.9 -0.53 -0.7 0.24 97 60.8 -0.54 1.6 0.24 97 62.5 
  Adj.MI -0.64 0.4 0.29 97 62.2 -0.62 -2.4 0.27 97 65.2 -0.64 0.5 0.27 97 69.4 
  Unadj.WGEE -0.52 -1.3 0.28 97 47.2 -0.50 -6.1 0.26 96 49.6 -0.54 2.7 0.26 96 55.4 
  Adj.WGEE -0.62 -2.4 0.31 96 53.5 -0.59 -7.1 0.29 95 55.0 -0.65 1.9 0.29 96 64.0 
MAR 50 Unadj.logit -0.38 -28.2 0.44 94 12.4 -0.19 -63.7 0.43 88 7.6 -0.70 31.7 0.43 94 35.5 
  Adj.logit -0.47 -26.5 0.49 94 15.8 -0.24 -62.6 0.48 85 7.6 -0.85 33.4 0.48 93 41.4 
  Unadj.GEE -0.54 2.6 0.54 94 17.0 -0.61 14.3 0.51 94 22.5 -0.49 -8.0 0.50 95 14.9 
  Adj.GEE -0.66 2.8 0.61 95 18.6 -0.72 12.2 0.57 94 23.3 -0.62 -3.9 0.57 95 17.7 
  Unadj.GLMM -0.63 18.2 0.60 95 16.9 -0.76 43.2 0.57 94 25.1 -0.47 -12.2 0.55 95 12.5 
  Adj.GLMM -0.71 10.8 0.64 95 19.1 -0.80 25.4 0.61 95 24.5 -0.61 -4.5 0.59 95 16.9 
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  Unadj.MI -0.54 1.5 0.53 97 13.2 -0.58 9.2 0.51 97 17.0 -0.52 -2.0 0.49 97 15.7 
  Adj.MI -0.65 1.0 0.61 97 13.4 -0.69 8.5 0.58 97 19.0 -0.63 -1.6 0.56 97 16.9 
  Unadj.WGEE -0.51 -3.0 0.69 94 11.9 -0.41 -23.3 0.62 94 10.9 -0.70 32.3 0.59 95 20.1 
  Adj.WGEE -0.63 -0.8 0.70 94 15.4 -0.54 -16.1 0.64 94 13.6 -0.81 27.0 0.62 94 25.3 
 200 Unadj.logit -0.37 -29.3 0.22 89 41.9 -0.18 -66.1 0.21 61 13.6 -0.68 27.8 0.21 89 88.9 
  Adj.logit -0.45 -29.5 0.24 87 48.4 -0.22 -65.9 0.23 55 15.4 -0.82 27.4 0.24 88 93.7 
  Unadj.GEE -0.53 0.3 0.26 96 52.7 -0.59 11.8 0.25 94 66.4 -0.46 -12.4 0.25 93 46.0 
  Adj.GEE -0.63 -1.1 0.29 95 57.5 -0.68 6.3 0.28 94 69.4 -0.58 -9.7 0.27 94 54.2 
  Unadj.GLMM -0.60 13.5 0.29 95 53.6 -0.72 36.6 0.28 90 74.5 -0.45 -15.9 0.27 93 37.1 
  Adj.GLMM -0.67 4.6 0.31 95 58.7 -0.75 16.8 0.29 93 73.6 -0.57 -11.3 0.28 94 50.0 
  Unadj.MI -0.53 0.4 0.26 97 53.5 -0.52 -2.3 0.25 97 55.8 -0.53 0.5 0.24 96 61.1 
  Adj.MI -0.64 -0.5 0.29 97 58.3 -0.62 -3.2 0.28 96 61.5 -0.64 -0.4 0.27 96 66.2 
  Unadj.WGEE -0.46 -13.7 0.40 96 24.2 -0.27 -48.5 0.35 91 14.9 -0.73 37.1 0.32 93 64.3 
  Adj.WGEE -0.57 -10.7 0.37 96 35.4 -0.41 -35.3 0.33 90 24.7 -0.81 25.9 0.31 92 74.7 
MNAR 50 Unadj.logit -0.46 -13.7 0.42 94 19.1 -0.38 -29.2 0.42 93 15.3 -0.60 12.3 0.42 96 30.5 
  Adj.logit -0.55 -13.5 0.46 94 21.7 -0.46 -28.3 0.46 92 17.1 -0.72 12.9 0.47 95 32.9 
  Unadj.GEE -0.55 4.2 0.54 94 17.8 -0.65 21.8 0.50 94 25.3 -0.46 -13.4 0.50 95 14.1 
  Adj.GEE -0.68 6.7 0.62 95 19.1 -0.77 20.3 0.57 95 26.2 -0.59 -8.2 0.57 95 16.9 
  Unadj.GLMM -0.61 14.2 0.60 94 16.4 -0.73 37.9 0.56 94 24.9 -0.48 -9.6 0.56 95 12.4 
  Adj.GLMM -0.71 11.7 0.65 95 18.7 -0.81 27.3 0.60 94 26.2 -0.61 -5.2 0.60 95 16.1 
  Unadj.MI -0.54 2.4 0.50 97 14.8 -0.62 16.3 0.48 97 22.1 -0.48 -9.4 0.48 97 13.9 
  Adj.MI -0.65 2.2 0.58 98 15.1 -0.75 16.5 0.55 97 23.8 -0.58 -9.1 0.55 97 13.3 
  Unadj.WGEE -0.53 -0.1 0.57 96 12.0 -0.55 2.8 0.53 96 16.0 -0.53 -0.8 0.53 96 14.9 
  Adj.WGEE -0.66 3.2 0.64 95 14.9 -0.70 9.0 0.59 96 21.4 -0.64 -0.7 0.58 95 17.6 
 200 Unadj.logit -0.47 -11.9 0.21 94 60.5 -0.37 -29.7 0.21 87 44.2 -0.58 9.5 0.21 95 79.1 
  Adj.logit -0.56 -13.1 0.23 92 67.9 -0.45 -30.4 0.23 86 50.4 -0.69 8.1 0.23 95 86.0 
  Unadj.GEE -0.55 2.9 0.26 95 54.8 -0.64 19.8 0.25 93 73.1 -0.43 -18.1 0.25 93 41.6 
  Adj.GEE -0.65 2.1 0.30 95 59.9 -0.73 14.7 0.28 94 76.0 -0.54 -15.3 0.27 93 50.1 
  Unadj.GLMM -0.59 11.6 0.29 95 53.5 -0.71 34.2 0.27 90 74.0 -0.46 -14.1 0.27 95 38.3 
  Adj.GLMM -0.68 5.7 0.31 95 58.9 -0.77 20.0 0.29 93 75.7 -0.56 -13.0 0.29 94 48.8 
  Unadj.MI -0.54 2.0 0.25 97 59.1 -0.59 10.8 0.24 96 70.8 -0.47 -11.8 0.24 97 50.8 
  Adj.MI -0.64 0.7 0.28 97 64.4 -0.70 9.4 0.27 97 76.8 -0.56 -12.9 0.27 96 56.8 
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  Unadj.WGEE -0.53 -0.2 0.28 97 48.8 -0.53 0.8 0.26 97 56.2 -0.51 -3.5 0.25 97 53.2 
  Adj.WGEE -0.64 -0.7 0.30 96 55.4 -0.66 2.9 0.28 96 65.7 -0.60 -6.7 0.28 96 58.0 
* Percentage of missing data for comparator and treatment, respectively; Cov: coverage of 95% CI; Rel Bias: relative Bias;  
Est: - log odds ratio; Boldface font indicates that the type I error rate is beyond 2 SEs of simulations. 
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Table 4. Analysis results from five diabetes clinical studies 
  Log odds 
ratio SE LL UL  p-value 
Study 1 Unadj.logit 0.90 0.18 0.54 1.27 <0.001 
 Adj.logit 1.20 0.21 0.77 1.62 <0.001 
 Unadj.GEE 0.84 0.19 0.46 1.22 <0.001 
 Adj.GEE 1.08 0.22 0.65 1.51 <0.001 
 Unadj.GLMM 1.12 0.27 0.58 1.67 <0.001 
 Adj.GLMM 1.26 0.27 0.72 1.81 <0.001 
 Unadj.MI 0.78 0.19 0.41 1.16 <0.001 
 Adj.MI 1.21 0.22 0.78 1.64 <0.001 
 Unadj.WGEE 0.80 0.20 0.41 1.19 <0.001 
 Adj.WGEE 0.93 0.21 0.50 1.36 <0.001 
Study 2 Unadj.logit 0.96 0.18 0.60 1.33 <0.001 
 Adj.logit 1.26 0.21 0.84 1.68 <0.001 
 Unadj.GEE 0.94 0.18 0.57 1.31 <0.001 
 Adj.GEE 1.26 0.22 0.82 1.71 <0.001 
 Unadj.GLMM 1.36 0.27 0.82 1.90 <0.001 
 Adj.GLMM 1.61 0.28 1.05 2.17 <0.001 
 Unadj.MI 0.93 0.18 0.57 1.30 <0.001 
 Adj.MI 1.22 0.21 0.79 1.64 <0.001 
 Unadj.WGEE 0.94 0.19 0.56 1.32 <0.001 
 Adj.WGEE 1.23 0.22 0.79 1.67 <0.001 
Study 3 Unadj.logit 0.47 0.18 0.12 0.82 0.007 
 Adj.logit 0.64 0.20 0.24 1.05 0.002 
 Unadj.GEE 0.43 0.19 0.06 0.81 0.021 
 Adj.GEE 0.59 0.21 0.16 1.01 0.006 
 Unadj.GLMM 0.65 0.31 0.02 1.28 0.038 
 Adj.GLMM 0.72 0.29 0.14 1.31 0.014 
 Unadj.MI 0.44 0.18 0.08 0.81 0.016 
 Adj.MI 0.57 0.21 0.16 0.98 0.005 
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 Unadj.WGEE 0.45 0.20 0.05 0.85 0.026 
 Adj.WGEE 0.63 0.22 0.19 1.07 0.004 
Study 4 Unadj.logit 0.38 0.17 0.03 0.72 0.028 
 Adj.logit 0.36 0.18 0.00 0.72 0.047 
 Unadj.GEE 0.45 0.18 0.10 0.81 0.011 
 Adj.GEE 0.49 0.19 0.12 0.87 0.009 
 Unadj.GLMM 0.63 0.23 0.17 1.10 0.007 
 Adj.GLMM 0.61 0.23 0.14 1.08 0.009 
 Unadj.MI 0.44 0.17 0.09 0.79 0.012 
 Adj.MI 0.43 0.18 0.06 0.79 0.019 
 Unadj.WGEE 0.50 0.19 0.13 0.88 0.008 
 Adj.WGEE 0.50 0.20 0.09 0.90 0.014 
Study 5 Unadj.logit 1.01 0.17 0.68 1.35 <0.001 
 Adj.logit 1.36 0.20 0.97 1.75 <0.001 
 Unadj.GEE 1.09 0.18 0.73 1.45 <0.001 
 Adj.GEE 1.41 0.21 1.00 1.83 <0.001 
 Unadj.GLMM 1.58 0.28 1.01 2.15 <0.001 
 Adj.GLMM 1.80 0.28 1.24 2.35 <0.001 
 Unadj.MI 1.03 0.17 0.69 1.38 <0.001 
 Adj.MI 1.34 0.20 0.94 1.74 <0.001 
 Unadj.WGEE 1.07 0.19 0.69 1.45 <0.001 
 Adj.WGEE 1.59 0.23 1.13 2.06 <0.001 
SE: standard error; LL: lower limit of 95% confidence interval; UL: upper limit of 95% confidence interval  
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